Clinical Trials in a Dish: A Perspective on the Coming Revolution in Drug Development

• Published in: SLAS discovery Vol. 23; no. 8; pp. 765 - 776
• Main Authors: Fermini, Bernard, Coyne, Shawn T., Coyne, Kevin P.
• Format: Journal Article
• Language: English
• Published: Los Angeles, CA SAGE Publications 01.09.2018
• Subjects: toxicology; stem cells; cell-based assays; cardiac diseases
• ISSN: 2472-5552; 2472-5560
• DOI: 10.1177/2472555218775028

The pharmaceutical industry is facing unprecedented challenges as the cost of developing new drugs has reached unsustainable levels, fueled in large parts by a high attrition rate in clinical development. Strategies to bridge studies between preclinical testing and clinical trials are needed to reduce the knowledge gap and allow earlier decisions to be made on the continuation or discontinuation of further development of drugs. The discovery and development of human induced pluripotent stem cells (hiPSCs) have opened up new avenues that support the concept of screening for cell-based safety and toxicity at the level of a population. This approach, termed “Clinical Trials in a Dish” (CTiD), allows testing medical therapies for safety or efficacy on cells collected from a representative sample of human patients, before moving into actual clinical trials. It can be applied to the development of drugs for specific populations, and it allows predicting not only the magnitude of effects but also the incidence of patients in a population who will benefit or be harmed by these drugs. This, in turn, can lead to the selection of safer drugs to move into clinical development, resulting in a reduction in attrition. The current article offers a perspective of this new model for “humanized” preclinical drug development.